Patents Examined by Gabriele Bugaisky
-
Patent number: 6720413Abstract: The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. CaSm contains the two Sm motifs found in the common snRNP proteins, with the greatest homology to the Sm G protein (60% similarity). The present invention further encompasses CaSm peptides, fusion proteins, host cell expression systems, antibodies to CaSm, antisense CaSM molecules, and compounds that modulate CaSm gene expression or CaSm activity. Antisense CaSm RNA is able to alter the transformed phenotype of pancreatic cancer cells by reducing their ability to form large colonies in soft agar when compared to untransfected cells. The present invention also encompasses methods for disease diagnosis, drug screening and the treatment of cancer.Type: GrantFiled: March 4, 1998Date of Patent: April 13, 2004Assignee: MUSC Foundation for Research DevelopmentInventors: Clifford W. Schweinfest, Takis S. Papas, Paul L. Baron, Dennis K. Watson
-
Patent number: 6716427Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.Type: GrantFiled: November 2, 2000Date of Patent: April 6, 2004Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 6689743Abstract: Disclosed claimed are toxins produced by novel Bacillus thuringiensis isolates designated B.t. PS92J, B.t. PS196S1, B.t. PS201L1, and B.t. PS201T6, which have dipteran and/or corn rootworm activity. Thus, the isolates, or mutants therof, can be used to control such pests. Further, claimed are novel genes encoding these &dgr;-endotoxins, which can be expressed in other hosts. Expression of the &dgr;-endotoxins in such hosts results in the control of susceptible insect pests in the environment of such hosts.Type: GrantFiled: November 3, 2000Date of Patent: February 10, 2004Assignee: Mycogen CorporationInventors: Jewel Payne, Kenneth E. Narva, Kendrick Akira Uyeda, Christine Julie Stalder, Tracy Ellis Michaels
-
Patent number: 6689750Abstract: A bacteriocin is obtained by culturing cells of a strain of Micrococcus varians which, upon culturing in a culture medium, produces a bacteriocin which has agar well incubation inhibition test activity against at least one of Lactobacillus, Lactococcus, Streptococcus, Enterococcus, Listeria, Bacillus, Clostridia and Straphylococcus bacteria. The strain is cultured to obtain cultured cells in a concentration of from 107 to 1011 organisms per ml of the medium, and the culture medium supernatant is separated from the cultured cells to obtain the supernatant which contains the bacteriocin, which is also identified by having an amino acid sequence from SEQ ID NO: 1 or a sequence differing from SEQ ID NO: 1 by from 1 to 4 amino acids.Type: GrantFiled: August 6, 1996Date of Patent: February 10, 2004Assignee: Nestec S.A.Inventors: Beat Mollet, John Peel, David Pridmore, Nadji Rekhif, Bruno Suri
-
Patent number: 6686459Abstract: The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.Type: GrantFiled: September 29, 1998Date of Patent: February 3, 2004Assignees: IDUN Pharmaceuticals, Inc., Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
-
Patent number: 6656908Abstract: Disclosed and claimed are novel Bacillus thuringiensis isolates, pesticidal toxins, genes, and nucleotide probes and primers for the identification of genes encoding toxins active against pests. The primers are useful in PCR techniques to produce gene fragments which are characteristic of genes encoding these toxins. The subject invention provides entirely new families of toxins from Bacillus isolates.Type: GrantFiled: May 7, 2001Date of Patent: December 2, 2003Assignee: Mycogen CorporationInventors: Jerald S. Feitelson, H. Ernest Schnepf, Kenneth E. Narva, Brian A. Stockhoff, James Schmeits, David Loewer, Charles Joseph Dullum, Judy Muller-Cohn, Lisa Stamp, George Morrill, Stacey Finstad-Lee
-
Patent number: 6653463Abstract: The invention relates to novel nucleic acid and protein sequences from the mung bean Vigna radiata. The nucleic acid sequence, isolated from a bruchid resistant mung bean line, encodes a thionin-like protein with insecticidal properties.Type: GrantFiled: October 11, 2000Date of Patent: November 25, 2003Assignee: Academia SinicaInventors: Ching-San Chen, Kuan-Chung Chen, Cheng-Chun Kuan, Ching-Yu Lin
-
Patent number: 6649161Abstract: A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.Type: GrantFiled: November 1, 2000Date of Patent: November 18, 2003Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 6635247Abstract: A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.Type: GrantFiled: April 16, 2001Date of Patent: October 21, 2003Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 6482636Abstract: The present invention provides constructed Bacillus thuringiensis (B.t.) strains that are toxic to mosquito larvae. The mosquito-toxic B.t. strains have improved characteristics, such as increased production of mosquito-toxic proteins, reduced number of spores or increased variety of mosquito-toxic proteins, compared with the well-known, mosquito-toxic strain Bacillus thuringiensis subspecies israelensis (B.t. israelensis). The present invention involves insertion of an antibiotic-resistance gene into the B.t. israelensis mosquito-toxin plasmid having a size of approximately 75 mDa such that the plasmid is “tagged” with antibiotic resistance. The advantage of the tagged mosquito-toxin plasmid is that it permits detection of the rare event in which the mosquito-toxin plasmid is transferred from the B.t. israelensis strain (the donor strain) into a non-B.t. israelensis strain (the recipient strain) that normally does not harbor the mosquito-toxin plasmid. Non-B.t.Type: GrantFiled: August 12, 1999Date of Patent: November 19, 2002Assignee: Certis USA, L.L.C.Inventors: William P. Donovan, James A. Baum
-
Patent number: 6194550Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA•polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA•polypeptide copolymers with an affinity to the target.Type: GrantFiled: November 23, 1998Date of Patent: February 27, 2001Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 5981184Abstract: A screening-model is disclosed for determining the inhibiting effect of substances on the P-type ATP-ase activity of Helicobacter. The screening model in question comprises: (a) a recombinant organism consisting of host cells transformed with at least one P-type ATP-ase gene which can be controlled via a promoter; (b) an inductor for gene activation of the P-type ATP-ase; (c) cations which inhibit the metabolic activity of the recombinant organism only in the presence of Helicobacter P-type ATP-ase; and (d) a measurement device for determining the metabolic activity of the recombinant organism.Type: GrantFiled: June 2, 1997Date of Patent: November 9, 1999Assignee: Byk Gulden Lomberg Chemische Fabrik GmbHInventor: Klaus Melchers
-
Patent number: 5753472Abstract: The present invention has disclosed the amino acid sequence and nucleotide sequence of the .alpha.- and .beta.-subunits of two types of nitrile hydratase derived from Rhodococcus rhodochrous J-1. The DNA fragment encoding nitrile hydratase is inserted into an expression vector and the recombinant vector is used for transformation. The transformant contains multiple copies of the gene and can produce much higher level of nitrile hydratase compared with conventionally used microorganisms.Type: GrantFiled: June 5, 1995Date of Patent: May 19, 1998Assignee: Nitto Chemical Industry Co. Ltd.Inventors: Hideaki Yamada, Toru Nagasawa, Teruhiko Beppu, Sueharu Horinouch, Makoto Nishiyama
-
Patent number: 5466593Abstract: A gene encoding a protease derived from human serum and having an activity to convert single-chain hepatocyte growth factor (HGF) into active two-chain HGF and a method of producing the protease by the use of said gene are provided. A method of producing a precursor protein of said protease is also provided.Type: GrantFiled: November 5, 1993Date of Patent: November 14, 1995Assignee: Mitsubishi Kasei CorporationInventors: Takeshi Shimomura, Kazunori Yamada, Yuuki Morimoto, Naomi Kitamura, Keiji Miyazawa
-
Patent number: 5358862Abstract: Synthetic tRNAs are produced from tRNA.sup.Cys (AAA), tRNA.sup.Ser (AAA), tRNA.sub.e.sup.Ala (AAA), and tRNA.sub.i.sup.Ala (AAA) genes. Polyuridylic acid-dependent syntheses of polypeptides were carried out in vitro on E. coli ribosomes using the synthetic tRNAs.Type: GrantFiled: July 14, 1992Date of Patent: October 25, 1994Assignee: Research Development FoundationInventors: Boyd Hardesty, Wendy L. Picking